Trevi Therapeutics stock heads toward November 9 results update

Trevi Therapeutics said on November 2 that it will report financial results for the quarter ended September 30 and provide a corporate update on November 9. The company’s announcement was carried by TradingView from GlobeNewswire.

November 9 results checkpoint

Senior management will host a conference call and live webcast on Monday, November 9, at 4:30 p.m. Eastern Time. The session will cover the third-quarter results and a corporate update, giving investors the next scheduled look at Trevi’s financial position and development program.

Registration is available through the company’s investor website. Trevi said an archived replay will remain available for 30 days after the webcast, extending access to the management update beyond the live event.

Clinical focus remains Haduvio

Trevi is developing Haduvio, an investigational oral extended-release formulation of nalbuphine, for chronic cough associated with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease and refractory chronic cough.

The company said clinical trials showed a statistically significant reduction in cough frequency and improvements in patient-reported outcomes in patients with IPF-related chronic cough and refractory chronic cough. Trevi also states that Haduvio’s safety and efficacy have not been evaluated by any regulatory authority, leaving clinical and regulatory execution as central considerations for investors.

Broader investor sentiment can be followed in Current market reports.